Advertisement

Topics

Janssen-Cilag AG Company Profile

09:20 EST 19th December 2018 | BioPortfolio

NIL

Location

Sihlbruggstrasse 111
Baar
6340
France

Contact

Phone: 41 (41) 767 34 34
Fax: 41 (41) 767 34 00
Email: info@jacch.jnj.com.


News Articles [362 Associated News Articles listed on BioPortfolio]

Janssen affiliate Cilag and Argenx sign deal for cancer therapy

Janssen Pharmaceutical affiliate Cilag International has signed a global collaboration and license agreement with Dutch biotechnology company Argenx for cusatuzumab...Read More... The post Janssen aff...

J&J/Janssen’s Cilag to Co-Develop argenx’s Cusatuzumab in $1.8B+ Collaboration

Cilag International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, will partner with argenx to develop its cancer-fighting antibody cusatuzumab (ARGX-110), through a c...

Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement ...

ZUG, Switzerland, December 3, 2018 /PRNewswire/ -- Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today it has Read more...

Cilag and Argenx in Cancer Drug Pact

Swiss-based Cilag, an affiliate of Janssen, the pharmaceuticals division of Johnson & Johnson, has entered into a global collaboration and license agreement with biotech company argenx to develop ...

Cilag gets global rights to argenx's cusatuzumab

Argenx SE licensed Janssen’s Cilag GMBH International exclusive global rights to its cusatuzumab (ARGX110) in blood cancers.

Cilag collaborates with argenx to develop and commercialise cancer immunotherapy cusatuzumab

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered into a worldwide collaboration and license agreement with argenx BVBA and argenx SE, to...

$JNJ Janssen Affiliate Cilag Enters Worldwide Collab and License Agreement with $ARGX for Cancer Immunotherapy Cusatuzumab. $300M upfront to $ARGX https://www.prnewswire.com/news-releases/janssen-affiliate-cilag-gmbh-international-enters-worldwide-collabo

$JNJ Janssen Affiliate Cilag Enters Worldwide Collab and License Agreement with $ARGX for Cancer Immunotherapy Cusatuzumab. $300M upfront to $ARGX

Janssen affiliate and Dutch company ink $1.6B deal to develop cancer drug

Cilag, an affiliate of Janssen, is teaming up with a Netherlands-based biopharmac company called Argenx to develop a treatment for certain cancers.

Drugs and Medications [39 Associated Drugs and Medications listed on BioPortfolio]

Long last make up 02 (neo heliopan) [Janssen Cosmetics GmbH]

Drug Facts

Risperidone [WOCKHARDT USA LLC.]

These highlights do not include all the information needed to use risperidone oral solution safely and effectively. See full prescribing information for risperidone oral solution. Risperidone Oral Sol...

Risperidone [WOCKHARDT LIMITED]

These highlights do not include all the information needed to use risperidone oral solution safely and effectively. See full prescribing information for risperidone oral solution. Risperidone Oral Sol...

Stelara [Janssen Biotech, Inc.]

These highlights do not include all the information needed to use STELARA safely and effectively. See full prescribing information for STELARA. STELARA (ustekinumab) Injection, for subcutaneous useIn...

Nizoral [Ortho-McNeil-Janssen Pharmaceuticals, Inc.]

Nizoral (ketoconazole) 2% Shampoo

PubMed Articles [6 Associated PubMed Articles listed on BioPortfolio]

Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.

Anemia is one of the most prevalent complications in patients with chronic kidney disease, which is believed to be caused by the insufficient synthesis of erythropoietin by the kidney. This phase III ...

An Analysis of Different Components of a High-Throughput Screening Library.

Since many projects at pharmaceutical organizations get their start from a high-throughput screening (HTS) campaign, improving the quality of the HTS deck can improve the likelihood of discovering a h...

Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade.

Biologics are produced from living organisms in complex, multi-stage manufacturing processes and contain inherent variability, which must be understood and controlled during manufacturing to avoid une...

Multiple-therapy-resistant major depressive disorder: a clinically important concept.

SummaryMany novel therapeutic options for depression exist that are either not mentioned in clinical guidelines or recommended only for use in highly specialist services. The challenge faced by clinic...

Determination of a Focused Mini Kinase Panel for Early Identification of Selective Kinase Inhibitors.

We analyzed an extensive data set of 3000 Janssen kinase inhibitors (spanning some 40 therapeutic projects) profiled at 414 kinases in the DiscoverX KINOMEscan to better understand the necessity of us...

Clinical Trials [18 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate the Efficacy and Safety of HX 575 vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving about 462 clinically stable hemodialysis patients aged 18 years or above suffering from anemia ...

Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients

This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged >18 years who are receiving palliative chemotherapy and who are suffering ...

Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder

The purpose of this study is to assess the usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in autism spectrum disorder (ASD) (severe abnorm...

A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Rabeprazole from Idiazole 20mg DR tabs (GSK, Egypt)and PARIET 20 mg DR tabs (JANS...

Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Rivaroxaban from Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Indust...

Companies [34 Associated Companies listed on BioPortfolio]

Janssen-Cilag EMEA, EMHF, ESHA & ISG

Janssen-Cilag EMEA, a division of Janssen Pharmaceutica N.V., is a research-based pharmaceutical company that develops and markets innovative, high-quality pharmaceutical products and services aim...

Janssen-Cilag International NV

Janssen-Cilag AG

NIL

Janssen-Cilag Farmacéutica

NIL

JANSSEN-ORTHO INC

Since 1961 Janssen-Cilag has been a member of the Johnson & Johnson family of companies. Founded in 1886, Johnson & Johnson today is the world's most comprehensive manufacturer of healthcare products ...

More Information about "Janssen-Cilag AG" on BioPortfolio

We have published hundreds of Janssen-Cilag AG news stories on BioPortfolio along with dozens of Janssen-Cilag AG Clinical Trials and PubMed Articles about Janssen-Cilag AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Janssen-Cilag AG Companies in our database. You can also find out about relevant Janssen-Cilag AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record